Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

Hepatology

Volumn 50, Issue 6, 2009, Pages 2001-2006

  Lange, Christian M ^a   Bojunga, Jörg ^a   Hofmann, Wolf Peter ^a   Wunder, Katrin ^a   Mihm, Ulrike ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASE; BILIRUBIN; CEFOTAXIME; CREATININE; ENTECAVIR; HYDROCHLOROTHIAZIDE; LACTIC ACID; LACTULOSE; LAMIVUDINE; LEVOFLOXACIN; MEROPENEM; METOPROLOL; PANTOPRAZOLE; PREDNISOLONE; PROPRANOLOL; RAPAMYCIN; SPIRONOLACTONE; TACROLIMUS; TENOFOVIR; TORASEMIDE; URSODEOXYCHOLIC ACID; VITAMIN K GROUP;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT INFECTION; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SCORING SYSTEM;

ACIDOSIS, LACTIC; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED;

EID: 73149085984     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23346     Document Type: Article

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virusDNA level. JAMA 2006;295:65-73.
3. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
4. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
5. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
6. Heathcote EJ, Gane E, de Man RA, Chan S, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate treatment and adefovir dipivoxil switch data in HBe-Ag-positive patients with chronic hepatitis B (study 103), preliminary analysis. HEPATOLOGY 2008;48(Suppl. 4):376.
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
8. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341; 1286.
9. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744.
10. Patel V, Hedayati SS. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy. Nat Clin Pract Nephrol 2006;2:109-114; 115.
11. Schiff E, Simsek H, LeeWM,Chao YC, SetteHJr, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-2783.
12. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008;22:1374-1376.
13. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. HEPATOLOGY 2009;49(Suppl. 5):185-195.
14. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. HEPATOLOGY 2009;49:2080-2086.
15. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
16. Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to Lamivudine administration in a liver transplant recipient. Am J Transplant 2005;5:634.
17. Bayrakci US, Baskin E, Ozcay F, Ozdemir BH, Karakayali H, Haberal M. Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008;12: 109-112.
18. Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009;43:1008-1010.
19. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605.
20. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-1448.